US Stock Market Closed

Dashboard

AVEO Pharmaceuticals, Inc. (AVEO)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

S

Analyst Opinion

S

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

CEO

Michael P. Bailey

Employees

19

Industry

Oncology Biopharmaceuticals

Sector

Healthcare

Headquarters

Boston

Exchange

NASDAQ

Summary Stats

Market Cap

521M

Revenue

94.3M

Net Income

-29M

EPS

-$0.84

Price-to-Earnings

-17.83

Price-to-Book

18.08

Debt-to-Equity

2.51

News

Analyst Ratings

Price targets projected by 4 analysts

High

$17.00

Average

$11.25

Low

$7.00

Ratings calculated by 0 analysts

Buy

0

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.09

Actual

-$0.09 +50.0%

Consensus

-0.18

Report Date

Year Ago

-0.3

Year Ago Change %

Up 70%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites